upper respiratory tract infection
Conditions
Interventions
Patients receive 1g of 50% tranexamic acid preparation three times a day.
Patients receive 1g placebo (lactose) three times a day.
Sponsors
Akashi Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients of upper respiratory tract infections with a complaint of sore throat, who visited a general internal medicine department office in trial hospital from July 2026 to March 2027 were registered.
Exclusion criteria
Exclusion criteria: Patients with allergy to tranexamic acid and lactose, pregnant patients or patients with possibility of pregnancy, breastfeeding patients, patients who take tranexamic acid, patients who were unable to participate the study because of dementia, visual impairment and unable to answer, or complete the study form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome is the difference on sore throat VAS scale between 1 day after tranexamic acid is taken. | — |
Secondary
| Measure | Time frame |
|---|---|
| The proportion of patients with sore throat score more than moderate level between 1 day after tranexamic acid is taken. | — |
Countries
Japan
Contacts
Public ContactNaoto Ishimaru
Akashi Medical Center Department of General Internal Medicine
Outcome results
None listed